Quotient Bioresearch has published a white paper titled 'Biomarkers in Metabolic Syndrome - Cardiovascular Disease and Type 2 Diabetes'.
The paper, available for download from the company's website, explores the multifaceted relationship between metabolic syndrome and the increased risk of developing cardiovascular disease (CVD) and type 2 diabetes mellitus (T2D).
It highlights how biomarkers of CVD and T2D can add value to drug discovery and development in this important therapeutic area.
David Griffiths, business-development director at Quotient Bioresearch, said: 'The mechanisms and pathways of metabolic syndrome are not completely known and, although it is generally agreed that weight, genetics, age and lifestyle are important factors leading to metabolic syndrome, the pathophysiology is intricate and its cause remains elusive.
'We have seen the role for biomarkers increase dramatically as companies look to understand the complex pathways leading to CVD and T2D,' he added.
Metabolic syndrome is a cluster of disorders that increases the risk of developing CVD and T2D.
It is thought to affect approximately one in five people, with some studies estimating the prevalence in the US and Europe to be as high as 25 per cent.
